Enhanced pneumocystis carinii activity of new primaquine analogues.
New analogues of the venerable antimalarial drug primaquine have been synthesized and bioassayed in vivo against Pneumocystis carinii, a life-threatening infection common among immunosuppressed patients. Two of these new compounds are significantly more active than primaquine itself, and provide new information for future drug design and development in this area.
Goodwin
T E
TE
Department of Chemistry, Hendrix College, Conway, AR 72032, USA. goodwin@hendrix.edu
Boylan
C J
CJ
Current
W L
WL
Byrd
J C
JC
Edwards
C B
CB
Fuller
D A
DA
Green
J L
JL
Larocca
C D
CD
Raney
K D
KD
Ross
A S
AS
Tucker
W A
WA
D000818:Animals; D000935:Antifungal Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D005260:Female; D006801:Humans; D015394:Molecular Structure; D011010:Pneumocystis / Q000187:drug effects; D016720:Pneumocystis Infections / Q000188:drug therapy*; D011319:Primaquine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; D011319:Primaquine